Bladder Cancer | Unmet Need | US/EU | 2020
The FDA approval of five immune checkpoint inhibitors for advanced or metastatic bladder cancer has significantly altered the treatment landscape, which has historically been dominated by chemotherapy regimens. However, only about 20% of patients will benefit from immune checkpoint inhibitor therapy, after which effective alternative therapies are severely limited. The FDA’s 2019 approval of Balversa (Johnson & Johnson) has provided an additional treatment option for the 15-20% of patients with susceptible FGFR alterations. However, given the dismal overall survival for patients with distant metastases, a significant level of unmet need remains in the bladder cancer drug market.
Questions Answered
- How important are clinical drug attributes in medical oncologists’ prescribing decisions? What are the key influencers on treatment decisions and the hidden opportunities that drug developers could leverage?
- How do key current therapies, such as Tecentriq (Roche) and Keytruda (Merck & Co.), perform on key clinical drug attributes for this patient population? Are medical oncologists satisfied with current therapies?
- What are the greatest unmet needs and most attractive opportunities in this patient population?
- What trade-offs are surveyed medical oncologists willing to make across key drug attributes and price when considering a hypothetical target product profile?
Product Description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in December 2019.
Key companies: Merck & Co., Roche / Genentech, Bristol-Myers Squibb, Merck KGaA / Pfizer, AstraZeneca, Johnson & Johnson.
Key drugs: Keytruda, Tecentriq, Opdivo, Bavencio, Imfinzi, Balversa.
